BASF Plans New World-Scale Ibuprofen Production Plant in Germany

BASF SE plans to build a new world-scale plant to produce ibuprofen in Ludwigshafen, Germany. Ibuprofen is an active pharmaceutical ingredient that is used for treating pain, fever, and inflammation. The new plant is scheduled to come onstream in 2021.

In addition, the company is also increasing its ibuprofen capacities at its production site in Bishop, Texas, to fill current supply gaps for ibuprofen in the market. The expansion will come onstream in early 2018. The company will invest approximately €200 million in both projects.

BASF has been manufacturing ibuprofen at its FDA-audited, cGMP-certified production site in Bishop for over 20 years. BASF operates an award-winning, eco-efficient production process that ensures the highest product quality levels.

“It will be the first world-scale ibuprofen plant in Europe. With this investment, BASF aims to ensure high supply security for its customers and meet growing global demand. BASF will be the only supplier with two ibuprofen assets worldwide. This makes us a highly reliable partner for our customers,” said Dr Markus Kamieth, member of the board of executive directors, BASF SE.

“Both investments show our strong commitment to the pharmaceutical industry and our pharma solutions business. They enable us to close supply gaps and efficiently support our customers’ growth plans,” added Dr Melanie Maas-Brunner, president of BASF’s nutrition & health business.